Outcomes after heart transplantation in patients with cardiac sarcoidosis. (15th January 2022)

• Record Type: Journal Article
• Authors: Asleh, Rabea; Briasoulis, Alexandros; Doulamis, Ilias; Alnsasra, Hilmi; Tzani, Aspasia; Alvarez, Paulino; Kuno, Toshiki; Kampaktsis, Polydoros; Kushwaha, Sudhir
• Is Part Of: ESC heart failure. Volume 9:Number 2(2022)
• Page Start: 1167
• Page End: 1174
• Publication Date: 2022-01-15
• Subjects: Cardiac sarcoidosis -- Heart transplantation -- Restrictive cardiomyopathy -- Dilated cardiomyopathy -- Outcomes; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13789
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Background: The number of patients with sarcoidosis requiring heart transplantation (HT) is increasing. The aim of this study was to evaluate outcomes of isolated HT in patients with sarcoid cardiomyopathy and compare them to recipients with non‐ischaemic restrictive or dilated cardiomyopathy. Methods and results: Adult HT recipients were identified in the UNOS Registry between 1990 and 2020. Patients were grouped according to diagnosis. The cumulative incidences for the all‐cause mortality and rejection were compared using Fine and Gray model analysis, accounting for re‐transplantation as a competing risk. Rejection was evaluated using logistic regression analysis. We also reviewed characteristics and outcomes of all HT recipients with previous diagnosis of sarcoid cardiomyopathy from a single centre. A total of 30 160 HT recipients were included in the present study ( n = 239 sarcoidosis, n = 1411 non‐ischaemic restrictive cardiomyopathy, and n = 28 510 non‐ischaemic dilated cardiomyopathy). During a total of 194 733 patient‐years, all‐cause mortality at the latest follow‐up was not significantly different when comparing sarcoidosis to non‐ischaemic dilated cardiomyopathy [adjusted subhazard ratio (aSHR) 1.46, 95% confidence intervals (CIs): 0.9–2.4, P = 0.12] or restrictive cardiomyopathy (aSHR 1.12, 95% CI: 0.65–1.95, P = 0.67). Accordingly, multivariable analysis suggested that 1 year mortality was not significantly different between sarcoidosis and non‐ischaemic dilated cardiomyopathy (aSHR 1.56, 95% CI: 0.9–2.7, P = 0.12) or restrictive cardiomyopathy (aSHR 1.15, 95% CI: 0.61–2.18, P = 0.66). No differences were observed regarding 30 day mortality, treated and hospitalized acute rejection, and 30 day death from graft failure after HT. Thirty‐day mortality did not improve significantly in more recent HT eras whereas there was a trend towards improved 1 year mortality in the latest HT era ( P = 0.06). Data from the single‐centre case review showed excellent long‐term outcomes with sirolimus‐based immunosuppression. Conclusions: Short‐term and long‐term post HT outcomes among patients with sarcoid cardiomyopathy are similar to those with common types of non‐ischaemic cardiomyopathy.